Adicet Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 143
- Market Cap
- -
- Website
- http://www.adicetbio.com
A Phase 1/2 Trial of ADI-270 in CcRCC
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT06480565
- Locations
- 🇺🇸
Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States
A Phase 1 Study of ADI-001 in Lupus Nephritis
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT06375993
- Locations
- 🇺🇸
The Feinstein Institutes for Medical Research - Northwell Health, Manhasset, New York, United States
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT04911478
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Baylor Scott & White Research Institute, Dallas, Texas, United States
A Phase 1 Study of ADI-001 in B Cell Malignancies
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 78
- Registration Number
- NCT04735471
- Locations
- 🇺🇸
Baylor Scott & White Research Institute, Dallas, Texas, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath